CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 267 enrolled
Drug / intervention
Pembrolizumab +7 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02039674
NCT02039674Phase 2Completed
CompareCT.gov

A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma

Merck Sharp & Dohme LLC·interventional·Posted Jan 17, 2014·Updated Nov 8, 2022

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab, Paclitaxel, and 6 other interventions for Non-small Cell Lung Carcinoma. Completed, enrolled 267 participants.

Detailed Summary

The purpose of this study is to determine the safety, tolerability, and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy or immunotherapy in participants with unresectable or metastatic non-small cell lung cancer (NSCLC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Carcinoma
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 17, 2014
Enrollment StartFeb 21, 2014
Primary CompletionNov 7, 2016
Study CompletionOct 18, 2021
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 12.5 years ago

Interventions

Pembrolizumabbiological

IV on Day 1 of each 3-week cycle prior to chemo/immunotherapy

Paclitaxeldrug

IV on Day 1 of each 3-week cycle for a maximum of 4 administrations

Carboplatindrug

IV on Day 1 of each 3-week cycle for a maximum of 4 administrations

Bevacizumabbiological

IV on Day 1 of each 3-week cycle

Pemetrexeddrug

IV on Day 1 of each 3-week cycle

Ipilimumabbiological

IV on Day 1 of each 3-week cycle for a maximum of 4 administrations

Erlotinibdrug

Orally tablet once daily

Gefitinibdrug

Oral tablet once daily